Evidence-based Mobile Medical Applications in Diabetes - 04/11/16
, Priya Prahalad, MD, PhD b, Deborah Greenwood, PhD, RN, CDE c, David C. Klonoff, MD, FRCP (Edin) dRésumé |
This article reviews mobile medical applications that are commercially available in the United States or European Union (EU) and are (1) associated with published data of clinical outcomes in the peer-reviewed literature during the past 5 years, (2) cleared by the US Food and Drug Administration (FDA) in the United States, or (3) a recipient of a CE (Conformité Européenne) mark by the EU. Many of these applications have been shown to positively affect outcomes in the short term, but long-term studies are needed. Until more data are available, consumers and professionals can consider guidance based on FDA/CE status.
Le texte complet de cet article est disponible en PDF.Keywords : Mobile, Medical, Applications, Diabetes, mHealth, Glucose, Telemedicine
Plan
| Disclosures: Dr A. Drincic is a consultant for Bayer. Dr D. Greenwood is a scientific advisor for Welkin Health. Dr D.C. Klonoff is a consultant for Bayer, Insuline, Lifecare, and Voluntis. Dr P. Prahalad has nothing to disclose. |
Vol 45 - N° 4
P. 943-965 - décembre 2016 Retour au numéro
Article précédent
- Understanding Population Health Through Diabetes Population Management
- Joanna Mitri, Robert Gabbay
- Transcultural Endocrinology : Adapting Type-2 Diabetes Guidelines on a Global Scale
- Ramfis Nieto-Martínez, Juan P. González-Rivas, Hermes Florez, Jeffrey I. Mechanick
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?